Filing Flows › Impact Biomedical (IBO) › Q3 2026
Impact Biomedical (IBO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Impact Biomedical (IBO) reported revenue of $21K for the third quarter 2026 (Q3 2026), +17% from a year earlier and +600% from the quarter before.
Impact Biomedical, Q3 2026: revenue $21K (+17% year over year), net loss $644K, operating cash flow $11K. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21K | +600% | +17% |
| Operating profit | −$648K | — | — |
| Net earnings | −$644K | — | — |
| Operating cash flow | $11K | -98% | — |
What changed
Revenue was $21K in Q3 2026, up 17% year over year and up 600% from the previous quarter.
Operating costs exceeded revenue by $648K, an operating margin of -3085.7%. Total costs fell 31% while revenue rose 17%. The fastest-growing cost line was Cost of revenue (+500%). The quarter ended with a net loss of $644K, narrower than the previous quarter's $700K loss.
Operating cash flow was $11K. Non-cash charges added back $284K of depreciation and amortization. Working capital and other items added $371K.
Questions
What was Impact Biomedical's revenue in the third quarter 2026?
Impact Biomedical (IBO) reported revenue of $21K for the third quarter 2026 (Q3 2026), +17% from a year earlier and +600% from the quarter before.
Source: Impact Biomedical 10-Q on SEC EDGAR.